SEC61A1 Antibody

What is SEC61A1 and what role does it play in cellular functions?

SEC61A1 (Sec61 alpha 1 subunit) is the primary component of the Sec61 translocon complex, essential for protein translocation across the endoplasmic reticulum (ER) membrane. This protein belongs to the SecY/SEC61-alpha family and has a molecular weight of approximately 52,265 daltons with two identified isoforms . The SEC61 complex forms a protein-conducting channel in the ER membrane, facilitating the transport of nascent polypeptides into the ER lumen or insertion into the ER membrane. This process is crucial for proper protein folding, modification, and eventual secretion or membrane insertion.

The functional significance of SEC61A1 extends beyond basic protein translocation, as it has been identified as a critical target in certain disease mechanisms, including toxin-mediated pathologies such as those caused by mycolactone from Mycobacterium ulcerans . Understanding SEC61A1 function is therefore essential for investigating various cellular processes including protein homeostasis, ER stress responses, and certain pathological conditions.

How should I select an appropriate SEC61A1 antibody for my specific research application?

When selecting a SEC61A1 antibody, consider these methodological criteria:

• Epitope specificity: Determine which region of SEC61A1 you need to target. C-terminal antibodies (such as ABIN2856382) are common and well-characterized . If you're investigating specific domains or isoforms, ensure the antibody's epitope aligns with your research focus.

• Application compatibility: Verify that the antibody has been validated for your intended application. For example, ABIN2856382 is validated for Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (IHC), and Immunocytochemistry (ICC) .

• Host species: Consider the host species (e.g., rabbit, goat) in relation to your experimental design, particularly if you're performing multi-label experiments with other antibodies .

• Clonality: Polyclonal antibodies offer broader epitope recognition, while monoclonal antibodies provide higher specificity. Most commercial SEC61A1 antibodies are polyclonal .

• Species cross-reactivity: Verify the antibody's reactivity with your experimental model organism. Some SEC61A1 antibodies show excellent cross-reactivity across multiple species (human, mouse, rat, zebrafish, etc.) .

• Validation documentation: Review literature citations and validation data provided by the manufacturer to confirm the antibody's performance in contexts similar to your planned experiments .

• Conjugation status: Determine whether you need a conjugated or unconjugated antibody based on your detection method .

What are the standard applications for SEC61A1 antibodies in research?

SEC61A1 antibodies support multiple experimental approaches in cellular and molecular biology:

Each application requires specific optimization for SEC61A1 detection, including appropriate blocking agents, antibody dilutions, and incubation conditions. For membrane proteins like SEC61A1, detergent selection during sample preparation significantly impacts experimental success.

How can I validate the specificity of a new SEC61A1 antibody?

Rigorous validation of SEC61A1 antibody specificity involves multiple complementary approaches:

• Positive and negative controls: Include tissue or cell lines known to express SEC61A1 as positive controls. For negative controls, consider using SEC61A1 knockout cells generated through CRISPR/Cas9 genome editing, as described in mycolactone studies .

• Western blot analysis: Confirm the antibody detects a single band at the expected molecular weight (~52 kDa) across different sample types. Multiple bands may indicate degradation products, isoforms, or non-specific binding.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide prior to application. Signal elimination or reduction confirms specificity for the target epitope.

• siRNA knockdown validation: Transfect cells with SEC61A1-specific siRNA and confirm signal reduction compared to control siRNA.

• Immunostaining pattern analysis: SEC61A1 should display characteristic ER localization, co-localizing with other ER markers like calnexin or PDI.

• Cross-species reactivity testing: If working with non-human models, verify reactivity with your species of interest. Some SEC61A1 antibodies show high conservation of reactivity across species (Mouse 100%, Rat 100%, Zebrafish 100%, Xenopus laevis 93%, etc.) .

• Mass spectrometry validation: For ultimate confirmation, perform immunoprecipitation followed by mass spectrometry to verify the identity of the captured protein.

What are the optimal protocols for using SEC61A1 antibody in Western blotting experiments?

Effective Western blotting with SEC61A1 antibodies requires specific considerations for this membrane protein:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors

  • Include 1% digitonin or NP-40 to solubilize membrane proteins

  • Avoid excessive heating (>70°C) which can cause aggregation of membrane proteins

• Gel selection and transfer:

  • Use 10-12% polyacrylamide gels for optimal separation

  • For transfer, PVDF membranes generally yield better results than nitrocellulose for membrane proteins

  • Transfer efficiency can be improved with the addition of 0.05% SDS to transfer buffer

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • For primary SEC61A1 antibody, typical dilutions range from 1:500 to 1:2000

  • Overnight incubation at 4°C often yields optimal results

• Signal detection optimization:

  • Enhanced chemiluminescence (ECL) detection systems work well

  • For weaker signals, consider using signal enhancers or higher sensitivity substrates

• Troubleshooting guidelines:

  • Multiple bands: May indicate protein degradation or post-translational modifications

  • No signal: Check transfer efficiency using Ponceau S staining

  • High background: Increase washing steps or reduce antibody concentration

This protocol has been validated with multiple SEC61A1 antibodies including rabbit polyclonal antibodies targeting the C-terminal region .

How should I design immunofluorescence experiments to study SEC61A1 localization?

Successful immunofluorescence protocols for SEC61A1 visualization require attention to fixation and permeabilization methods to preserve ER structure:

• Cell preparation and fixation:

  • Culture cells on glass coverslips to 60-80% confluence

  • Fix with 4% paraformaldehyde in PBS for 15 minutes at room temperature

  • For improved epitope accessibility, consider methanol fixation (-20°C, 10 minutes)

• Permeabilization and blocking:

  • Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

  • Block with 3% BSA in PBS containing 0.1% Tween-20 for 1 hour

• Antibody incubation:

  • Dilute SEC61A1 primary antibody (typically 1:100 to 1:500) in blocking buffer

  • Incubate overnight at 4°C in a humidified chamber

  • After washing, apply fluorophore-conjugated secondary antibody (1:500) for 1 hour at room temperature

• Co-localization studies:

  • Co-stain with established ER markers (e.g., calnexin, PDI, or KDEL-containing proteins)

  • Include DAPI (1:1000) for nuclear counterstaining

  • For multi-labeling experiments, ensure primary antibodies are from different host species to avoid cross-reactivity

• Imaging parameters:

  • Use confocal microscopy for optimal resolution of ER structures

  • Capture z-stacks to fully visualize the three-dimensional ER network

  • Include appropriate controls for autofluorescence and bleed-through

• Data analysis:

  • Quantify co-localization using Pearson's or Mander's coefficients

  • For distribution changes, measure intensity profiles across defined cellular regions

The characteristic pattern for SEC61A1 should show reticular ER distribution, potentially with perinuclear enrichment .

What controls are essential when working with SEC61A1 antibodies?

Robust experimental design with SEC61A1 antibodies requires several types of controls:

• Antibody specificity controls:

  • Primary antibody omission: Reveals non-specific binding of secondary antibody

  • Isotype control: Use non-specific IgG from the same host species and at the same concentration

  • Peptide competition: Pre-incubation with immunizing peptide should abolish specific signal

  • SEC61A1 knockdown or knockout cells: CRISPR/Cas9-edited cells lacking SEC61A1 expression serve as negative controls

• Sample processing controls:

  • Positive control tissues/cells: Include samples known to express SEC61A1

  • Loading controls: Use housekeeping proteins (β-actin, GAPDH) for Western blots

  • Subcellular fraction purity controls: When isolating ER fractions, verify with markers for ER and other organelles

• Technical controls:

  • Secondary antibody only: Evaluate background fluorescence

  • Autofluorescence control: Unstained samples to establish baseline signal

  • Cross-reactivity control: When performing multiple immunostaining, include single-stained samples

• Experimental validation controls:

  • Biological replicates: Multiple independent samples

  • Technical replicates: Repeated measures of the same sample

  • Alternative antibody validation: Confirm key findings with a second antibody targeting a different epitope of SEC61A1

Inclusion of these controls increases confidence in experimental findings and facilitates troubleshooting when unexpected results occur.

How can SEC61A1 antibodies be used to study ER stress responses?

SEC61A1 antibodies serve as valuable tools for investigating the relationship between protein translocation and ER stress pathways:

• Co-immunoprecipitation studies:

  • Use SEC61A1 antibodies to isolate the translocon complex

  • Identify interaction partners under normal versus stress conditions

  • Analyze post-translational modifications that may regulate SEC61A1 function during stress

• Stress pathway activation analysis:

  • Monitor changes in SEC61A1 localization or expression during ER stress

  • Correlate with established ER stress markers (e.g., phosphorylated eIF2α, which has been linked to SEC61A1 in mycolactone studies)

  • Track SEC61A1 associations with chaperones during unfolded protein response

• Experimental stress induction protocols:

  • Chemical inducers: Tunicamycin (glycosylation inhibitor), thapsigargin (SERCA inhibitor), DTT (reducing agent)

  • Compare with physiological stressors: Glucose deprivation, hypoxia, viral infection

  • Examine SEC61A1 involvement in toxin-induced stress, as demonstrated with mycolactone

• Quantitative analysis approaches:

  • Flow cytometry with phospho-specific antibodies for ER stress markers

  • Live-cell imaging using tagged SEC61A1 constructs during stress induction

  • Temporal analysis of SEC61A1 complex remodeling during stress resolution

• Therapeutic intervention studies:

  • Test compounds that may modulate SEC61A1 function during stress

  • Evaluate SEC61A1-targeted approaches for diseases with ER stress components

Research has demonstrated that SEC61A1 is a critical mediator in mycolactone-induced ER stress, particularly affecting eIF2α phosphorylation and subsequent caspase-dependent apoptosis . This suggests SEC61A1 may serve as a therapeutic target in diseases involving ER stress dysregulation.

What methodological approaches can be used to study SEC61A1 in protein translocation defects?

Investigating SEC61A1's role in protein translocation defects requires specialized techniques:

• In vitro translocation assays:

  • Prepare microsomes from cells with normal or manipulated SEC61A1 expression

  • Use radiolabeled or fluorescently tagged nascent proteins as translocation substrates

  • Measure translocation efficiency through protease protection assays

  • Analyze effects of SEC61A1 antibodies when added to the translocation reaction

• Reporter protein systems:

  • Design dual reporter constructs with ER-targeted signal sequences

  • Quantify translocation efficiency in cells with modified SEC61A1 expression

  • Assess post-translational modifications dependent on proper translocation

• SEC61A1 mutagenesis studies:

  • Generate point mutations in functional domains of SEC61A1

  • Evaluate effects on specific substrate translocation

  • Correlate with disease-associated mutations

• Ribosome-translocon complex analysis:

  • Use cryo-electron microscopy to visualize SEC61A1 in active translocation complexes

  • Perform ribosome profiling to identify translational pauses associated with SEC61A1 dysfunction

  • Analyze polysome profiles in cells with normal versus altered SEC61A1 function

• Integrated multi-omics approach:

  • Proteomics: Identify substrates most affected by SEC61A1 alterations

  • Transcriptomics: Analyze compensatory responses to SEC61A1 dysfunction

  • Interactomics: Map changes in the SEC61A1 interactome under different conditions

These methodologies have revealed that SEC61A1 dysfunction can lead to substrate-specific translocation defects rather than global translocation failure, suggesting differential substrate sensitivity to SEC61A1 alterations.

How can CRISPR/Cas9 genome editing of SEC61A1 enhance functional studies?

CRISPR/Cas9 technology has revolutionized SEC61A1 functional analysis through precise genetic manipulation:

• Knockout strategy design:

  • Target early exons to ensure complete protein loss

  • Use specific sgRNA sequences (e.g., 5'-GCCTGGCGTTGAATTGGTG-3') that have been validated in previous studies

  • Implement inducible systems for studying essential genes like SEC61A1

• Verification methods:

  • PCR amplification and sequencing of the targeted region

  • Western blot confirmation of protein loss using validated SEC61A1 antibodies

  • Functional assays to confirm translocation defects

• Phenotypic characterization approaches:

  • Viability and growth curve analysis

  • ER morphology assessment by electron microscopy

  • Secretory pathway functional analysis

• Rescue experiments:

  • Complementation with wild-type SEC61A1 to confirm specificity

  • Structure-function analysis using mutant variants

  • Domain-swap constructs to identify functional regions

• Disease-relevant applications:

  • Generation of cell models with disease-associated SEC61A1 mutations

  • Testing sensitivity to toxins like mycolactone in edited cells

  • Screening for compounds that modify SEC61A1-dependent phenotypes

CRISPR/Cas9 editing has been successfully employed to create SEC61A1-knockout THP-1 cells, which demonstrated suppression of mycolactone-induced endoplasmic reticulum stress and caspase-dependent apoptosis, confirming SEC61A1 as an essential mediator of mycolactone toxicity .

What is the role of SEC61A1 in pathogen-host interactions and how can it be studied?

SEC61A1's critical role in pathogen-host interactions, particularly as a target for bacterial toxins, can be investigated through multiple approaches:

• Toxin-translocon interaction studies:

  • Direct binding assays between purified toxins and SEC61A1

  • Competition experiments with antibodies targeting different SEC61A1 epitopes

  • Structural analysis of toxin-SEC61A1 complexes

• Cellular pathology assessment:

  • Comparative analysis of wild-type versus SEC61A1-deficient cells exposed to toxins

  • Time-course imaging of cellular changes following toxin exposure

  • Correlation between SEC61A1 engagement and downstream effects

• Signaling pathway analysis:

  • Phosphoproteomic profiling to identify toxin-induced signaling events dependent on SEC61A1

  • Pathway inhibitor studies to dissect SEC61A1-dependent signaling cascades

  • Single-cell analysis to capture heterogeneity in responses

• Genome-wide screening approaches:

  • CRISPR screens to identify genes that modify SEC61A1-dependent toxin sensitivity

  • Transcriptome analysis of host response in the presence/absence of SEC61A1

  • Proteome-wide analysis of changes in protein synthesis and degradation

• Therapeutic development strategies:

  • High-throughput screening for compounds that disrupt toxin-SEC61A1 interactions

  • Development of decoy peptides based on SEC61A1 binding sites

  • Evaluation of SEC61A1-targeting antibodies as toxin neutralization agents

Research has demonstrated that SEC61A1 is the primary target of mycolactone, a toxin produced by Mycobacterium ulcerans that causes Buruli ulcer. Genome-wide screening identified SEC61A1 as the highest scoring among 884 genes potentially involved in mycolactone-induced cell death, and knockout of SEC61A1 suppressed mycolactone-induced ER stress and apoptosis . This supports SEC61A1 as a potential therapeutic target for toxin-mediated diseases.

What are common challenges when working with SEC61A1 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with SEC61A1 antibodies:

These troubleshooting approaches have been validated in multiple research contexts and can significantly improve experimental outcomes when working with SEC61A1 antibodies.

How can I optimize immunoprecipitation protocols for SEC61A1 and its interaction partners?

Successful immunoprecipitation of SEC61A1 and its binding partners requires specialized approaches for membrane proteins:

• Optimization of lysis conditions:

  • Test different detergent combinations (digitonin, DDM, CHAPS) that preserve protein-protein interactions

  • Maintain physiological salt concentrations (120-150 mM NaCl) to preserve weak interactions

  • Include phosphatase inhibitors to maintain post-translational modification states

• Cross-linking approaches:

  • Consider mild cross-linking (0.5-1% formaldehyde, 10 minutes) to stabilize transient interactions

  • DSP (dithiobis[succinimidyl propionate]) can be useful as it's cleavable for downstream analysis

  • Optimize cross-linker concentration and time to avoid over-cross-linking

• Antibody selection and coupling:

  • Choose antibodies validated for immunoprecipitation applications

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Consider covalent coupling of antibodies to beads to avoid antibody contamination in mass spectrometry

• Washing optimization:

  • Start with mild washing conditions and increase stringency as needed

  • Consider detergent reduction in later washes to preserve weaker interactions

  • Include controls washed at different stringencies to identify specific versus non-specific interactions

• Elution strategies:

  • For mass spectrometry: On-bead digestion often yields better results for membrane proteins

  • For Western blotting: Standard SDS elution buffer with heating at 70°C (not 95°C) to avoid aggregation

  • For native complexes: Consider competitive elution with immunizing peptide

• Controls and validation:

  • IgG control from same species as SEC61A1 antibody

  • Reciprocal IP with antibodies against suspected interaction partners

  • Validation of key interactions with orthogonal methods (proximity ligation assay, FRET)

These optimized protocols facilitate the identification of both stable and transient SEC61A1 interaction partners, providing insights into the dynamic composition of the translocon complex under different cellular conditions.

What quantitative approaches can be used to measure SEC61A1 expression or modification levels?

Accurate quantification of SEC61A1 expression and modifications requires appropriate methodological approaches:

• Western blot quantification:

  • Use gradient gels (4-15%) for optimal separation

  • Include recombinant SEC61A1 standards for absolute quantification

  • Apply appropriate normalization (total protein staining preferred over single housekeeping proteins)

  • Use fluorescent secondary antibodies for wider linear range compared to chemiluminescence

  • Analyze using software with background subtraction and lane normalization features

• qPCR for transcript analysis:

  • Design primers spanning exon-exon junctions to avoid genomic DNA amplification

  • Validate primer efficiency using standard curves

  • Use multiple reference genes for normalization

  • Consider digital PCR for absolute quantification

• Mass spectrometry approaches:

  • Targeted proteomics (SRM/MRM) for specific SEC61A1 peptides

  • SILAC labeling for comparing SEC61A1 levels across conditions

  • Phosphoproteomics workflows for quantifying specific modifications

  • TMT labeling for multiplexed comparison across multiple conditions

• Flow cytometry for single-cell analysis:

  • Permeabilization optimization for accessing intracellular epitopes

  • Use fluorescence minus one (FMO) controls for gating

  • Consider phospho-specific antibodies for modification analysis

  • Combine with cell cycle markers for cell-cycle dependent changes

• Imaging-based quantification:

  • High-content screening approaches for population-level analysis

  • FRAP (Fluorescence Recovery After Photobleaching) for SEC61A1 dynamics

  • Ratiometric imaging with tagged constructs for live-cell quantification

  • Super-resolution microscopy for quantifying nanoscale distribution

These quantitative approaches enable precise measurement of SEC61A1 expression and modifications across different experimental contexts, facilitating comparative studies and mechanism elucidation.

How can SEC61A1 antibodies be used to investigate the role of SEC61A1 in neurodegenerative diseases?

Emerging research suggests potential links between SEC61A1 function and neurodegenerative processes that can be explored using SEC61A1 antibodies:

• Protein misfolding investigation:

  • Evaluate SEC61A1 interactions with disease-associated proteins (Aβ, tau, α-synuclein)

  • Analyze SEC61A1 distribution in affected versus unaffected brain regions

  • Assess SEC61A1 complex integrity in disease models

• ER stress in neurodegeneration:

  • Quantify SEC61A1 expression relative to ER stress markers in neurodegenerative disease models

  • Investigate temporal relationships between SEC61A1 alterations and disease progression

  • Test whether SEC61A1 modulation affects neuronal vulnerability to stress

• Specialized techniques for neuronal systems:

  • Primary neuronal cultures with SEC61A1 manipulation (knockdown/overexpression)

  • Brain organoid models for studying SEC61A1 in human neuronal contexts

  • In vivo studies using viral-mediated SEC61A1 modification in specific brain regions

• Co-localization with disease markers:

  • Perform multi-label immunofluorescence with SEC61A1 antibodies and disease-specific markers

  • Apply super-resolution microscopy for nanoscale distribution analysis

  • Quantify changes in SEC61A1 distribution in relation to protein aggregates

• Therapeutic target evaluation:

  • Screen for compounds that normalize SEC61A1 function in disease models

  • Test whether SEC61A1 stabilization affects disease progression

  • Investigate potential for SEC61A1-targeted peptides as therapeutic agents

This research direction could provide valuable insights into the contribution of protein translocation defects to neurodegenerative pathologies and identify novel intervention strategies.

What are the latest developments in using SEC61A1 as a target in toxin-related diseases?

Recent research has highlighted SEC61A1's critical role in toxin-mediated pathologies, particularly Buruli ulcer caused by Mycobacterium ulcerans:

• Genome-wide screening findings:

  • SEC61A1 was identified as the highest-scoring gene among 884 candidates in a genome-scale CRISPR mutagenesis screen for factors involved in mycolactone-induced cell death

  • CRISPR/Cas9 editing of SEC61A1 in THP-1 cells suppressed mycolactone-induced ER stress and caspase-dependent apoptosis

• Mechanistic pathway elucidation:

  • Mycolactone targeting of SEC61A1 triggers specific ER stress pathways, particularly eIF2α phosphorylation

  • The relationship between SEC61A1 inhibition and downstream effects provides a model for understanding toxin-induced pathologies

• Therapeutic development approaches:

  • Screening for compounds that block toxin-SEC61A1 interaction while preserving normal function

  • Development of decoy peptides based on toxin binding sites on SEC61A1

  • Investigation of stress pathway modulators as adjunctive therapy to antibiotic treatment

• Translational research directions:

  • Testing whether SEC61A1-targeted interventions can reduce Buruli ulcer pathology in animal models

  • Development of diagnostic approaches based on SEC61A1-toxin interactions

  • Extension of findings to other diseases involving ER stress and protein translocation defects

• Methodological advances:

  • Development of cell-based assays for high-throughput screening of SEC61A1-protective compounds

  • Creation of reporter systems for monitoring SEC61A1 function in disease models

  • Application of structural biology approaches to design targeted interventions

These developments suggest that SEC61A1-targeted interventions could provide novel therapeutic strategies for toxin-mediated diseases, potentially supplementing current treatments like the 8-week antibiotic regimen of rifampicin and clarithromycin for Buruli ulcer .

How can combining SEC61A1 antibodies with other research tools enhance our understanding of protein translocation dynamics?

Integrating SEC61A1 antibodies with complementary research tools creates powerful approaches for studying translocon dynamics:

• Multi-modal imaging approaches:

  • Correlative light and electron microscopy (CLEM): Use SEC61A1 antibodies for fluorescence imaging followed by EM to visualize translocon ultrastructure

  • Super-resolution microscopy with SEC61A1 antibodies combined with live-cell imaging of tagged substrates

  • Single-molecule tracking of translocation events in conjunction with fixed-cell SEC61A1 immunostaining

• Functional genomics integration:

  • CRISPR screens for modifiers of SEC61A1 function combined with SEC61A1 antibody-based phenotypic assays

  • Transcriptome analysis correlated with SEC61A1 protein levels and distribution

  • Genetic variant analysis coupled with SEC61A1 functional assays

• Biochemical approach combinations:

  • Mass spectrometry identification of SEC61A1 interactors following antibody-based purification

  • Hydrogen-deuterium exchange mass spectrometry to map structural changes upon substrate binding

  • Cross-linking mass spectrometry to capture transient interactions during translocation

• Systems biology frameworks:

  • Mathematical modeling of SEC61A1-mediated translocation informed by quantitative antibody-based measurements

  • Network analysis of SEC61A1 interactions under different cellular conditions

  • Proteome-wide analysis of translocation efficiency correlated with SEC61A1 status

• Temporal analysis methods:

  • Pulse-chase experiments combined with SEC61A1 immunoprecipitation

  • Time-resolved cryo-electron microscopy with antibody labeling

  • Optogenetic manipulation of SEC61A1 function coupled with real-time imaging

These integrated approaches enable researchers to bridge structural, functional, and dynamic aspects of SEC61A1 biology, providing comprehensive insights into protein translocation mechanisms in normal and disease states.